These promising data on the safety and tolerability as well as improvement in RNFL thickness over a 1-month course of treatment, together with strong neuroprotective effects in preclinical studies, encourage the initiation of larger and broader studies to further evaluate topical insulin in glaucoma. This evidence concerns the gene INS and glaucoma.